A Phase 3 Multicenter Study of Gleolan (Aminolevulinic Acid Hydrochloride) to Enhance Visualization of Tumor in Patients with Newly Diagnosed or Recurrent Meningiomas
MD Anderson Study Status
Gleolan (Aminolevulinic Acid Hydrochloride/ALA/ALA-HCI)
This Phase 3 open-label single-arm study is designed to investigate the safety, diagnostic performance, and clinical usefulness of Gleolan for the real time detection and visualization of meningiomas during tumor resection surgery. The study is planned to run for 15 months with individual study participation lasting for approximately 2 months.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
For general questions about clinical trials: